A phase II trial of dose-reduced nab -paclitaxel for patients with previously treated, advanced or recurrent gastric cancer (OGSG 1302)
ConclusionTri-weeklynab-PTX with a reduced dose (220 mg/m2) is not recommended for AGC in a second-line or later setting, despite demonstrating less toxicity than at 260 mg/m2.Clinical trial registrationThe OGSG1302 trial was registered with UMIN-CTR as UMIN000000714.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Abraxane | Adenocarcinoma | Anemia | Anorexia | Brain | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Eating Disorders & Weight Management | Gastric (Stomach) Cancer | Gastroenterology | Japan Health | Nanotechnology | Neurology | Peripheral Neuropathy | Toxicology